Supernus Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
18.6%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$885.8Mnext fiscal year
FY EPS (est.)
$2.57next fiscal year
Monitoring Framework
Key Performance Indicators
Qelbree Net Product Sales Quarterly77.9M
ONAPGO Net Product Sales Quarterly8.4M
ZURZUVAE Collaboration Revenue Quarterly27.6M
GOCOVRI Net Product Sales Quarterly35.2M
Watch Items
- ONAPGO Second Supplier FDA Regulatory SubmissionTrigger: Submission targeted for Q3 2026Action: Monitor FDA acceptance of filing and potential approval timeline by mid-year 2027 to resolve supply constraints.
- SPN-820 (NV-5138) Phase 2b Clinical Trial ProgressTrigger: Completion of Phase 2b study in Major Depressive Disorder (MDD)Action: Evaluate clinical efficacy and safety data; determine whether to exercise the escape clause or proceed with development and trigger milestone payments up to $350 million.
- Erosion of Legacy Products (Trokendi XR and Oxtellar XR)Action: Assess the rate of generic erosion and ensure growth products (Qelbree, ONAPGO, ZURZUVAE) sufficiently offset the decline.
Research as of 20 Jun 2026